The biomanufacturing sector is witnessing shifts towards continuous production models promising higher yields, lower costs, and environmental benefits. Companies like Enzene Biosciences employ fully connected continuous manufacturing (FCCM) powered by Xcell ATF technology, achieving up to a 10-fold productivity increase and 80% reduced cost of goods compared to traditional batch processes. Concurrently, AI-powered platforms such as Katalyze AI’s Digityze AI transform unstructured manufacturing documents into structured data to enhance compliance and analytics in biomanufacturing workflows. These advancements are addressing challenges in scalability, quality control, and operational efficiency in biologics production, setting new industry standards.